Recent Updates
Recently added Catalysts

BMS-986147

Phase 1

Healthy | Small molecule | Other |Bristol-Myers Squibb Company|Last Updated: May 19, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment8

FDA Designations

No designations recorded

Clinical trial landscape

BMS-986147 · 1 trial · 1 indication

Phase 1 1
NCT02293629A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy SubjectsHealthy
COMPLETED8 Analytics
PHASE1COMPLETED
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects
Healthy
NCT022936298
Unlock trial analytics

Study Endpoints

Primary Endpoints

Safety and tolerability of single oral dose of BMS-986147 based on incidence of AEs, serious AEs, AEs leading to discontinuation, and death as well as marked abnormalities in clinical laboratory tests, vital sign measurements, and physical examinations
Up to 30 days post last dose of study drug

Adverse event (AE)

Safety and tolerability of multiple oral dose of BMS-986147 based on incidence of AEs, serious AEs, AEs leading to discontinuation, and death as well as marked abnormalities in clinical laboratory tests, vital sign measurements, and physical examinations
Up to 30 days post last dose of study drug
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelFACTORIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
A1: BMS-986147 or Placebo matching BMS-986147PLACEBO_COMPARATORSingle oral dose as specified
A2: BMS-986147 or Placebo matching BMS-986147PLACEBO_COMPARATORSingle oral dose as specified
A3: BMS-986147 or Placebo matching BMS-986147PLACEBO_COMPARATORSingle oral dose as specified
B1: BMS-986147 or Placebo matching BMS-986147ACTIVE_COMPARATORDaily oral dose as specified
B2: BMS-986147 or Placebo matching BMS-986147ACTIVE_COMPARATORDaily oral dose as specified

Interventions

NameTypeDescription
BMS-986147DRUG -
Placebo matching BMS-986147DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy men and women, ages 18 to 45 years * Subjects must not have clinically significant deviation from normal: medical history, physical examination, ECGs and laboratory e...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about BMS-986147

What is BMS-986147?

BMS-986147 is an investigational small molecule being developed by Bristol-Myers Squibb Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy subjects to evaluate its safety, pharmacokinetics, and target engagement.

What is BMS-986147 used for?

BMS-986147 is being studied in healthy volunteers as part of early clinical development. The completed Phase 1 trial assessed the drug's safety, pharmacokinetics, and target engagement in healthy subjects. Its intended therapeutic use has not been established.

Who makes BMS-986147?

BMS-986147 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy subjects.

What phase is BMS-986147 in?

BMS-986147 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It is not approved by the FDA and is still undergoing clinical evaluation.

What clinical trials is BMS-986147 in?

BMS-986147 has one completed clinical trial, NCT02293629, titled "A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects." This Phase 1 study enrolled 8 participants in the United States.

How does BMS-986147 work?

BMS-986147 is a small molecule. The Phase 1 trial was designed to evaluate its target engagement in healthy subjects, but the specific molecular target has not been disclosed in available information.